Stocks Comparison
Astrazeneca vs ELI LILLY: revenue, profit, margins and growth compared
Astrazeneca brought in $58.7B of revenue in fiscal 2025, ELI LILLY $65.2B in fiscal 2025. Revenue changed by +8.6% at Astrazeneca and +44.7% at ELI LILLY on the year before, so ELI LILLY grew faster. Astrazeneca kept 17.4% of its revenue as net profit, ELI LILLY 31.7%.
Side by side, latest fiscal year
| AZN | LLY | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $58.7B | $65.2B |
| Revenue growth | +8.6% | +44.7% |
| Net income | $10.2B | $20.6B |
| Net margin | 17.4% | 31.7% |
| Free cash flow | $11.8B | n/a |
| Free cash flow margin | 20.0% | n/a |
| Earnings per share (diluted) | $6.54 | $22.95 |
| Cash | $5.7B | $7.3B |
| Debt | $29.6B | $40.9B |
| Price to earnings | n/a | 51.6 |
| Market value | $258.3B | $1.11T |
| Dividend yield | n/a | 0.53% |
| Rank by revenue in sector | #15 of 523 · Health care | #11 of 523 · Health care |
Over the years
Questions about Astrazeneca and ELI LILLY
Which is bigger by revenue, Astrazeneca or ELI LILLY?
ELI LILLY is bigger by revenue: $65.2B in fiscal 2025, against $58.7B for Astrazeneca in fiscal 2025.
Which keeps more of its revenue as profit, Astrazeneca or ELI LILLY?
Astrazeneca had a net margin of 17.4% in fiscal 2025; ELI LILLY had 31.7% in fiscal 2025.
Which grew revenue faster, Astrazeneca or ELI LILLY?
In their latest fiscal years revenue changed by +8.6% at Astrazeneca and +44.7% at ELI LILLY.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.